<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40289">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02040623</url>
  </required_header>
  <id_info>
    <org_study_id>C-932348-004</org_study_id>
    <nct_id>NCT02040623</nct_id>
  </id_info>
  <brief_title>To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Chronic Ocular Graft Versus Host Disease (DROPS-2)</brief_title>
  <acronym>DROPS-2</acronym>
  <official_title>A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to
           subjects evaluated by objective and subjective measures.

        -  To investigate the safety and tolerability of R348 Ophthalmic Solutions administered
           for 12 weeks to subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean change of total Corneal fluorescein staining score</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Keratoconjunctivitis Sicca in Patients With Chronic Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>R348 Ophthalmic Solution, 0.2%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R348 Ophthalmic Solution, 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Ophthalmic Solution 2 drops per eye twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R348 Ophthalmic Solution, 0.2%</intervention_name>
    <arm_group_label>R348 Ophthalmic Solution, 0.2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R348 Ophthalmic Solution, 0.5%</intervention_name>
    <arm_group_label>R348 Ophthalmic Solution, 0.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Ophthalmic Solution</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Received an Allogeneic hematologic stem cell transplantation at least 3 months prior.

          -  Subjects with post Allogeneic hematologic stem cell transplantation  onset or
             worsening of dry eye symptoms for at least 1 month prior.

          -  Use of over-the-counter and/or prescription eye drops for dry eye symptoms within 1
             month.

          -  Corneal fluorescein staining score of ≥ 2 in 1 region and ≥ 1 in at least 1 other
             region.

          -  Total lissamine green conjunctival staining score (according to a modified National
             Eye Institute grading system) of ≥ 2.

        Exclusion Criteria:

          -  Clinically unstable Graft versus Host Disease (requiring a change in
             immunosuppressive regimen), medical condition, or laboratory abnormality

          -  Used topical ophthalmic cyclosporine within 45 days.

          -  Used any topical ophthalmic steroid within 2 weeks.

          -  Used autologous serum eye drops within 2 weeks.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>U. Miami - Bascom Palmer Eye Institute</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victor Perez, MD</last_name>
      <phone>305-326-6302</phone>
    </contact>
    <investigator>
      <last_name>Victor Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reza Dana, MD</last_name>
      <phone>617-573-4331</phone>
    </contact>
    <investigator>
      <last_name>Reza Dana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>January 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Graft versus Host Disease</keyword>
  <keyword>Keratoconjunctivitis Sicca</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
